Andrew Dold, DO
Infectious Disease · Dacula, GANPI 1073718516
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.9%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Paratek Pharmaceuticals, Inc. at 52.9% of the total. Among infectious disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,715 payments — averaging $422.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$607K
- Insmed, Inc.$163K
- Viiv Healthcare Company$124K
- Melinta Therapeutics, LLC$86K
- Gilead$43K
- Merck$26K
- plus $99K from 27 others
What the payments were for
- Consulting fees$90,8418%
- Speaking & faculty fees$617,97154%
- Travel & lodging$376,82433%
- Food & beverage$59,5325%
- Education$2,0310%
- Gifts$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 1,035 | $606,903 |
| Insmed, Inc. | 366 | $162,681 |
| Viiv Healthcare Company | 255 | $124,481 |
| Melinta Therapeutics, LLC | 264 | $85,549 |
| Gilead | 143 | $42,583 |
| Merck | 91 | $25,866 |
| Ferring Pharmaceuticals Inc. | 45 | $20,430 |
| AbbVie(2 entities) | 85 | $18,714 |
| Astellas Pharma US Inc | 58 | $18,618 |
| Cumberland Pharmaceuticals, Inc. | 28 | $10,739 |
| Tetraphase Pharmaceuticals, Inc. | 20 | $9,723 |
| Shionogi Inc | 28 | $9,616 |
| Pfizer | 55 | $4,182 |
| Johnson & Johnson(2 entities) | 74 | $1,212 |
| Cipla USA Inc. | 6 | $1,173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 50 | $1,121 |
| Regeneron Healthcare Solutions, Inc. | 2 | $1,013 |
| Theratechnologies Inc. | 21 | $441 |
| Grifols USA, LLC | 18 | $421 |
| La Jolla Pharmaceutical Company | 20 | $391 |
| Octapharma USA, Inc. | 9 | $296 |
| Janssen Products, LP | 4 | $189 |
| CSL Behring | 6 | $154 |
| Nabriva Therapeutics, PLC | 8 | $150 |
| EMD Serono, Inc. | 6 | $113 |
| ADMA Biomanufacturing LLC | 3 | $101 |
| Aimmune Therapeutics, Inc. | 3 | $83 |
| Napo Pharmaceuticals Inc | 3 | $73 |
| Mayne Pharma Commercial LLC | 4 | $70 |
| Angiodynamics, Inc. | 1 | $46 |
| Amgen | 2 | $34 |
| GRT US Holding, Inc. | 1 | $19 |
| Pharming Healthcare, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,147,204 in reported general payments places this provider in the 95th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 106 | $1,611,232 |
| NuzyraOmadacycline Tosylate | 104 | $911,650 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 171 | $717,663 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 83 | $241,681 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 27 | $178,126 |
| JulucaDolutegravir/Rilpivirine | 45 | $157,259 |
| XembifyImmune Globulin,gamma(Igg)klhw | 12 | $144,946 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 29 | $138,261 |
| RukobiaFostemsavir Tromethamine | 13 | $135,696 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 22 | $121,071 |
| DovatoDolutegravir Sodium/Lamivudine | 32 | $98,564 |
| CresembaIsavuconazonium Sulfate | 12 | $77,859 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 18 | $69,292 |
| KimyrsaOritavancin Diphosphate | 13 | $66,891 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 12 | $54,906 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Insmed, Inc.Arikayce | $162,681 | $1,611,232106 claims |
| Paratek Pharmaceuticals, Inc.Nuzyra | $606,903 | $911,650104 claims |
| GileadBiktarvy | $42,583 | $717,663171 claims |
| Viiv Healthcare CompanyJuluca, Rukobia, Dovato, Triumeq | $124,481 | $460,812108 claims |
| Grifols USA, LLCGamunex-C, Xembify | $421 | $386,62895 claims |
| CSL BehringPrivigen | $154 | $178,12627 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $1,121 | $121,07122 claims |
| Astellas Pharma US IncCresemba | $18,618 | $77,85912 claims |
| Melinta Therapeutics, LLCKimyrsa | $85,549 | $66,89113 claims |
| Janssen Products, LPSymtuza | $189 | $54,90612 claims |
| PfizerPanzyga | $4,182 | $44,96211 claims |
| MerckPifeltro | $25,866 | $24,00514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 260 infectious disease providers in Georgia.
Other infectious disease in Dacula
- Zandraetta Tims-CookAtlanta$848K
- Jeffrey StephensMacon$356K
- Jose VazquezAugusta$335K
- Larry AndersonAtlanta$300K
- Quintin RobinsonAtlanta$270K
- James McMillenAtlanta$177K
- Leandro MenaAtlanta$141K
- Cheryl NewmanAugusta$128K
- Colleen KraftAtlanta$103K
- Adam BresslerGainesville$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.